Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Madrigal Pharmaceuticals
ISIN US5588681057
|WKN A2APCZ
Market cap (in EUR)
10,213 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 10,213 m |
| EPS, EUR | -11.05 |
| P/B ratio | 21.9 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 850 m |
| Net income, EUR | -256 m |
| Profit margin | -30.08% |
What ETF is Madrigal Pharmaceuticals in?
There are 33 ETFs which contain Madrigal Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Madrigal Pharmaceuticals is the Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.